HRP20150428T1 - 11-(2-pirolidin-1-il-etoksi)-14,19-dioksa-5,7,26-triaza-tetraciklo[19.3.1.1(2,6).1(8,12)]heptakoza-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaen citratna sol - Google Patents

11-(2-pirolidin-1-il-etoksi)-14,19-dioksa-5,7,26-triaza-tetraciklo[19.3.1.1(2,6).1(8,12)]heptakoza-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaen citratna sol

Info

Publication number
HRP20150428T1
HRP20150428T1 HRP20150428TT HRP20150428T HRP20150428T1 HR P20150428 T1 HRP20150428 T1 HR P20150428T1 HR P20150428T T HRP20150428T T HR P20150428TT HR P20150428 T HRP20150428 T HR P20150428T HR P20150428 T1 HRP20150428 T1 HR P20150428T1
Authority
HR
Croatia
Prior art keywords
heptakoza
dekaen
tetracyclo
triaza
dioxa
Prior art date
Application number
HRP20150428TT
Other languages
English (en)
Croatian (hr)
Inventor
Brian Dymock
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Original Assignee
Cti Biopharma Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cti Biopharma Corp. filed Critical Cti Biopharma Corp.
Publication of HRP20150428T1 publication Critical patent/HRP20150428T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
HRP20150428TT 2008-12-11 2009-12-09 11-(2-pirolidin-1-il-etoksi)-14,19-dioksa-5,7,26-triaza-tetraciklo[19.3.1.1(2,6).1(8,12)]heptakoza-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaen citratna sol HRP20150428T1 (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
EP09788621.2A EP2376499B1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Publications (1)

Publication Number Publication Date
HRP20150428T1 true HRP20150428T1 (xx) 2015-06-19

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150428TT HRP20150428T1 (xx) 2008-12-11 2009-12-09 11-(2-pirolidin-1-il-etoksi)-14,19-dioksa-5,7,26-triaza-tetraciklo[19.3.1.1(2,6).1(8,12)]heptakoza-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaen citratna sol

Country Status (23)

Country Link
US (2) US8980873B2 (enExample)
EP (1) EP2376499B1 (enExample)
JP (1) JP5669748B2 (enExample)
KR (1) KR101729918B1 (enExample)
CN (1) CN102282148B (enExample)
AR (2) AR074724A1 (enExample)
AU (1) AU2009325147B2 (enExample)
BR (1) BRPI0922736B1 (enExample)
CA (1) CA2746058C (enExample)
DK (1) DK2376499T3 (enExample)
ES (1) ES2536558T3 (enExample)
HR (1) HRP20150428T1 (enExample)
IL (3) IL213418A0 (enExample)
MX (1) MX2011006206A (enExample)
MY (1) MY160005A (enExample)
NZ (1) NZ593223A (enExample)
PL (1) PL2376499T3 (enExample)
PT (1) PT2376499E (enExample)
RU (1) RU2527970C2 (enExample)
SG (1) SG171907A1 (enExample)
TW (1) TWI449705B (enExample)
WO (1) WO2010068181A1 (enExample)
ZA (1) ZA201104032B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2376500T3 (pl) * 2008-12-11 2015-07-31 Cti Biopharma Corp Sól maleinianowa 11-(2-pirrolidyn-1-yloetoksy)-14,19-dioksa-5,7,26 triazatetracyklo[19.3.1.1(2,6).1(8,12)]heptakosa-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaenu
CN102282148B (zh) 2008-12-11 2014-12-24 Cti生物医药有限公司 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐
US9090623B2 (en) 2012-04-13 2015-07-28 Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. Compound JK12A and preparation thereof
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
CA2446988A1 (en) * 2001-05-14 2002-11-21 Pfizer Products Inc. The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
IL161326A0 (en) * 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CN101360751B (zh) 2005-11-16 2011-09-14 S*Bio私人有限公司 氧连接的嘧啶衍生物
CN102282148B (zh) 2008-12-11 2014-12-24 Cti生物医药有限公司 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐

Also Published As

Publication number Publication date
RU2011126173A (ru) 2013-01-20
WO2010068181A1 (en) 2010-06-17
JP5669748B2 (ja) 2015-02-12
MY160005A (en) 2017-02-15
US8980873B2 (en) 2015-03-17
CN102282148B (zh) 2014-12-24
DK2376499T3 (en) 2015-05-04
US20150322084A1 (en) 2015-11-12
IL289379A (en) 2022-02-01
RU2527970C2 (ru) 2014-09-10
IL250310A0 (en) 2017-03-30
EP2376499B1 (en) 2015-02-25
AU2009325147B2 (en) 2014-08-14
NZ593223A (en) 2013-08-30
PT2376499E (pt) 2015-06-03
JP2012511571A (ja) 2012-05-24
TWI449705B (zh) 2014-08-21
PL2376499T3 (pl) 2015-07-31
CA2746058C (en) 2016-05-17
TW201028426A (en) 2010-08-01
ES2536558T3 (es) 2015-05-26
AR114133A2 (es) 2020-07-22
BRPI0922736A2 (pt) 2017-10-31
KR20110106344A (ko) 2011-09-28
CN102282148A (zh) 2011-12-14
MX2011006206A (es) 2011-07-20
SG171907A1 (en) 2011-07-28
WO2010068181A8 (en) 2011-08-18
AR074724A1 (es) 2011-02-09
HK1161877A1 (en) 2012-08-10
KR101729918B1 (ko) 2017-04-25
IL213418A0 (en) 2011-07-31
CA2746058A1 (en) 2010-06-17
US20110294831A1 (en) 2011-12-01
US9624242B2 (en) 2017-04-18
BRPI0922736A8 (pt) 2021-11-09
BRPI0922736B1 (pt) 2022-02-22
ZA201104032B (en) 2012-08-29
EP2376499A1 (en) 2011-10-19
AU2009325147A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
CY2018024I2 (el) Παραγωγα διοξα-δικυκλο[3.2.1]οκταν-2,3,4-τριολης
NO2017026I1 (no) Alectinib (9-etyl-6,6-dimetyl-8-(4-morfolin-4-yl-piperidin-1-yl)-11-okso-6,11-dihydro-5H-benzo[b]-karbasol-3-karbonitril) eller salt eller solvat derav. (krav 1 i patentet)
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
DOP2007000080A (es) Piridin [3,4-b] pirazinonas
DK2326665T3 (da) Ikke-cytotoksiske fusionproteiner, omfattende egf-muteiner
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
BRPI0923732A2 (pt) &#34;regeneração de catalisador&#34;.
BRPI0923048A2 (pt) &#34;composto de aminopirazol&#34;.
IL289379A (en) Citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-19,14-dioxa-26,7,5-triaza-tetracyclo[1.1.3.19(6,2)1(12,8)]hepatacosa- 1(25),2(26),12,10,8,5,3(27)j23,21,16–Decan
AP2283A (en) Stable aqueous suspension.
HRP20150413T8 (xx) 11-(2-pirolidin-1-il-etoksi)-14,19-dioksa-5,7,26-triaza-tetraciklo[19.31.1(2,6).1(8,12)]heptakoza-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaen maleatna sol
NL1032046A1 (nl) Prostaglandinederivaten.
DK2454266T3 (da) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaen-citratsalt
EP2264029A4 (en) 1,3-dihydroisobenzofuran DERIVATIVE
BRPI1011720A2 (pt) compostos de 1,1,1- tri-flúor-2 hidróxi-propila.
BRPI0811655A2 (pt) &#34;artigo absorvente de formato alongado&#34;.
BRPI0918503A2 (pt) processo de preparação da 1,6:2,3-dianidro-beta-d-manopiranose
TH0901005537B (th) 11-(2-ไพร์โรลิดิน-1-อิล-เอทอกซี)-14,19-ไดออกซา-5,7,26-ไตรอะซา-เตตราไซโคล[19.3.1.1(2,6).1(8,12)]เฮปทาโคซา-1(25),2(26),3,5,8,10,12(27),16,21,23-เดคาอีน มาลีเอท ซอลท์
ITRM20080426A1 (it) Organostagno(iv) complessi con n-acetilcisteina ad attività antitumorale, procedimento per la loro produzione e loro uso.
ES1063937Y (es) Coche infantil plegable.
IT1392179B1 (it) Pannolino per l&#39;incontinenza leggera, particolarmente per signora.
ITBO20060032U1 (it) Contenitore per le feci.
ES1061047Y (es) Mesa carretilla plegable.
ITBO20060250A1 (it) Contenitore per feci.